Management Team

Tony Isaac has been a director of the Company since May 2015 and Chief Executive Officer of the Company since May 2016. He served as Interim Chief Executive Officer of the Company from February 2016 until May 2016. Mr. Isaac has served as Financial Planning and Strategist/Economist of Live Ventures Incorporated (Nasdaq: LIVE), a holding company for diversified businesses, since July 2012. He is the Chairman and Co-Founder of Isaac Organization, a privately held investment company. Mr. Isaac has invested in various companies, both private and public from 1980 to present. Mr. Isaac’s specialty is negotiation and problem-solving of complex real estate and business transactions. Mr. Isaac has served as a director of Live Ventures Incorporated since December 2011. Mr. Isaac graduated from Ottawa University in 1981, where he majored in Commerce and Business Administration and Economics.

As an experienced researcher and bioscientist, Dr. Giordano has held senior positions at cutting-edge biotechnology companies. As President of Sulfagenix, Inc., he managed the completion of a Phase 1 clinical study, GRAS affirmation and launch of medical food product. As Chief Executive Officer of Theravasc, Inc., he managed collaborations and development of a new drug formulation, TV1001SR, that JanOne recently licensed, and oversaw and managed the Phase 1 clinical study and two-Phase 2 studies. He also held senior positions at Message Pharmaceuticals, Inc., Nucleonics, Inc., and Alteris, Inc. 

Prior to Theravasc, Dr. Giordano had served as an Adjunct Professor of Biology at Case Western University, Special Advisor to the Chancellor at LSU Health Sciences Shreveport and as the Assistant Dean of Research and Business Development at Louisiana State University's Health & Sciences Center, where he worked with faculty to define the commercial potential of their research and identified and brought in funding through sponsored research agreements. Additionally, Dr. Giordano served as Director of Experimental Therapeutics in the Feist-Weiller Cancer Center, and as Associate Professor in the Departments of Pharmacology and Biochemistry. 

He served as advisor to three biotechnology venture capital funds, a consultant to the Biomedical Research Foundation, and was appointed by the Governor of Louisiana to the Innovation Council. Dr. Giordano has more than 20 issued patents and a number of pending patent applications and has published more than 50 research studies. Before beginning his career in biotech, Dr. Giordano was a senior scientist at Abbott Laboratories. Dr. Giordano earned a Ph.D. in Molecular Genetics at Ohio State University.

Mr. Johnson was appointed Chief Financial Officer of the Company on August 21, 2017. Mr. Johnson had previously served the Company as a consultant beginning in February 2017. Mr. Johnson also continues to serve as Chief Financial Officer for Live Ventures Incorporated, a holding company of diversified businesses (Nasdaq: LIVE). Prior to joining Live Ventures Incorporated, Mr. Johnson was Sr. Director of Revenue for JDA Software from February 2010 to April 2016, where he was responsible for revenue recognition determination, sales and contract support while acting as a subject matter expert. Prior to joining JDA, Mr. Johnson provided leadership and strategic direction while serving in C-Level executive roles in public and privately held companies such as Cultural Experiences Abroad, Inc., Fender Musical Instruments Corp., Triumph Group, Inc., Unitech Industries, Inc. and Younger Brothers Group, Inc. Mr. Johnson’s more than 25 years of experience is primarily in the areas of process improvement, complex debt financings, SEC and financial reporting, turn-arounds, corporate restructuring, global finance, merger and acquisitions and returning companies to profitability and enhancing stockholder value. Mr. Johnson holds a Bachelor’s degree in Accountancy from Arizona State University.